NO310072B1 - Pyrimidinderivater som 5HT2C-reseptor antagonister - Google Patents

Pyrimidinderivater som 5HT2C-reseptor antagonister Download PDF

Info

Publication number: NO310072B1
Authority: NO; Norway
Prior art keywords: formula; compound; methoxy; dihydrobenzo; quinazoline
Prior art date: 1995-10-02

Application number

NO981477A

Other languages

English (en)

Norwegian (no)

Other versions

NO981477L (no

NO981477D0 (no

Inventor

Lee Allen Flippin

Gabriel Stone Weatherhead

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-02

Filing date

1998-04-01

Publication date

2001-05-14

1998-04-01 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1998-04-01 Publication of NO981477D0 publication Critical patent/NO981477D0/no

1998-06-02 Publication of NO981477L publication Critical patent/NO981477L/no

2001-05-14 Publication of NO310072B1 publication Critical patent/NO310072B1/no

Links

102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title claims description 36
229940044551 receptor antagonist Drugs 0.000 title claims description 30
239000002464 receptor antagonist Substances 0.000 title claims description 30
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title claims description 29
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 2
150000003230 pyrimidines Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 137
238000000034 method Methods 0.000 claims description 37
238000011282 treatment Methods 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
239000001257 hydrogen Substances 0.000 claims description 20
229910052739 hydrogen Inorganic materials 0.000 claims description 20
201000010099 disease Diseases 0.000 claims description 18
230000001225 therapeutic effect Effects 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 12
-1 1-methyl-1H-indol-5-yl Chemical group 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
231100000252 nontoxic Toxicity 0.000 claims description 9
230000003000 nontoxic effect Effects 0.000 claims description 9
208000019695 Migraine disease Diseases 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 8
206010027599 migraine Diseases 0.000 claims description 8
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
208000019906 panic disease Diseases 0.000 claims description 7
208000007848 Alcoholism Diseases 0.000 claims description 6
201000007930 alcohol dependence Diseases 0.000 claims description 6
150000001450 anions Chemical class 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
208000019116 sleep disease Diseases 0.000 claims description 6
208000000103 Anorexia Nervosa Diseases 0.000 claims description 5
208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
208000029364 generalized anxiety disease Diseases 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
201000011264 priapism Diseases 0.000 claims description 5
239000000018 receptor agonist Substances 0.000 claims description 4
229940044601 receptor agonist Drugs 0.000 claims description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
125000005036 alkoxyphenyl group Chemical group 0.000 claims description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
208000020685 sleep-wake disease Diseases 0.000 claims 1
125000003107 substituted aryl group Chemical group 0.000 claims 1
229910052717 sulfur Inorganic materials 0.000 claims 1
239000011593 sulfur Chemical group 0.000 claims 1
238000002360 preparation method Methods 0.000 description 55
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
239000000203 mixture Substances 0.000 description 49
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 34
239000000243 solution Substances 0.000 description 28
239000002904 solvent Substances 0.000 description 23
230000000694 effects Effects 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
238000012360 testing method Methods 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 17
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 15
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
208000019901 Anxiety disease Diseases 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
230000036506 anxiety Effects 0.000 description 12
239000000047 product Substances 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
241000699670 Mus sp. Species 0.000 description 11
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
239000008194 pharmaceutical composition Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000009472 formulation Methods 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
229910052943 magnesium sulfate Inorganic materials 0.000 description 7
235000019341 magnesium sulphate Nutrition 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
101150013372 Htr2c gene Proteins 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
241000700159 Rattus Species 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000000949 anxiolytic effect Effects 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
239000000126 substance Substances 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
239000002585 base Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
208000011117 substance-related disease Diseases 0.000 description 5
239000000725 suspension Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
XBSMHLZMLQNTLY-UHFFFAOYSA-N 3,4,5-trimethoxy-n-methylaniline Chemical compound CNC1=CC(OC)=C(OC)C(OC)=C1 XBSMHLZMLQNTLY-UHFFFAOYSA-N 0.000 description 4
XEFRNCLPPFDWAC-UHFFFAOYSA-N 3,4,5-trimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 4
DVHUCYYOVSNIPN-UHFFFAOYSA-N 4-ethoxy-3,5-dimethoxyaniline Chemical compound CCOC1=C(OC)C=C(N)C=C1OC DVHUCYYOVSNIPN-UHFFFAOYSA-N 0.000 description 4
108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 4
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 4
MTXHQLZDDPFKIF-UHFFFAOYSA-N 5-methoxy-1-oxo-3,4-dihydro-2h-naphthalene-2-carbaldehyde Chemical compound O=C1C(C=O)CCC2=C1C=CC=C2OC MTXHQLZDDPFKIF-UHFFFAOYSA-N 0.000 description 4
QQOBKYGBIJJNBU-UHFFFAOYSA-N 5-methoxy-2-(methoxymethylidene)-3,4-dihydronaphthalen-1-one Chemical compound C1=CC=C2C(=O)C(=COC)CCC2=C1OC QQOBKYGBIJJNBU-UHFFFAOYSA-N 0.000 description 4
KYNQIOILLIMRAL-UHFFFAOYSA-N 6-methoxy-2-(methoxymethylidene)-3,4-dihydronaphthalen-1-one Chemical compound COC1=CC=C2C(=O)C(=COC)CCC2=C1 KYNQIOILLIMRAL-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
206010013654 Drug abuse Diseases 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000001913 cellulose Chemical class 0.000 description 4
229920002678 cellulose Chemical class 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
239000008103 glucose Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000001630 malic acid Substances 0.000 description 4
235000011090 malic acid Nutrition 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 4
229950009626 ritanserin Drugs 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
239000002484 serotonin 2C antagonist Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
UGOXYXBNKXBHAB-UHFFFAOYSA-N 1-oxo-3,4-dihydro-2h-naphthalene-2-carbaldehyde Chemical class C1=CC=C2C(=O)C(C=O)CCC2=C1 UGOXYXBNKXBHAB-UHFFFAOYSA-N 0.000 description 3
XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
FANQHCLSTNAJAC-UHFFFAOYSA-N 2-methylsulfanyl-5,6-dihydrobenzo[h]quinazoline Chemical class C1=CC=C2C3=NC(SC)=NC=C3CCC2=C1 FANQHCLSTNAJAC-UHFFFAOYSA-N 0.000 description 3
BRCPWISABURVIH-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C1C=CC=C2OC BRCPWISABURVIH-UHFFFAOYSA-N 0.000 description 3
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 3
PABZLPNUVFIDEB-UHFFFAOYSA-N 7-methoxy-2-methylsulfanyl-5,6-dihydrobenzo[h]quinazoline Chemical compound C1CC2=CN=C(SC)N=C2C2=C1C(OC)=CC=C2 PABZLPNUVFIDEB-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
208000030814 Eating disease Diseases 0.000 description 3
208000019454 Feeding and Eating disease Diseases 0.000 description 3
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
230000006399 behavior Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
229960003920 ***e Drugs 0.000 description 3
239000013078 crystal Substances 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
235000014632 disordered eating Nutrition 0.000 description 3
238000009509 drug development Methods 0.000 description 3
NKSMNLGPPHFQHA-UHFFFAOYSA-N ethyl n-(3,4,5-trimethoxyphenyl)carbamate Chemical compound CCOC(=O)NC1=CC(OC)=C(OC)C(OC)=C1 NKSMNLGPPHFQHA-UHFFFAOYSA-N 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229910017604 nitric acid Inorganic materials 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
239000006179 pH buffering agent Substances 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000011160 research Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000003997 social interaction Effects 0.000 description 3
229940035044 sorbitan monolaurate Drugs 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical compound COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 2
ARTJMIFJJBCYIO-UHFFFAOYSA-N 2-(methoxymethylidene)-3,4-dihydronaphthalen-1-one Chemical class C1=CC=C2C(=O)C(=COC)CCC2=C1 ARTJMIFJJBCYIO-UHFFFAOYSA-N 0.000 description 2
OHDURDXCCGUNOA-UHFFFAOYSA-N 2-ethoxy-1,3-dimethoxy-5-nitrobenzene Chemical compound CCOC1=C(OC)C=C([N+]([O-])=O)C=C1OC OHDURDXCCGUNOA-UHFFFAOYSA-N 0.000 description 2
COPJTXDDUKMXHR-UHFFFAOYSA-N 2-ethoxy-1,3-dimethoxybenzene Chemical compound CCOC1=C(OC)C=CC=C1OC COPJTXDDUKMXHR-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
108091005479 5-HT2 receptors Proteins 0.000 description 2
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 2
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
LRRRMDQSJIJQSI-UHFFFAOYSA-N 8-methoxy-2-methylsulfanyl-5,6-dihydrobenzo[h]quinazoline Chemical compound N1=C(SC)N=C2C3=CC=C(OC)C=C3CCC2=C1 LRRRMDQSJIJQSI-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
101000742062 Bos taurus Protein phosphatase 1G Proteins 0.000 description 2
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical class OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
229920005372 Plexiglas® Polymers 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000001668 ameliorated effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
235000013985 cinnamic acid Nutrition 0.000 description 2
229930016911 cinnamic acid Natural products 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
235000011087 fumaric acid Nutrition 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011539 homogenization buffer Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
229960005417 ketanserin Drugs 0.000 description 2
239000008101 lactose Chemical class 0.000 description 2
239000010410 layer Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
230000006742 locomotor activity Effects 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229960002510 mandelic acid Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002609 medium Substances 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
229940107700 pyruvic acid Drugs 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000002400 serotonin 2A antagonist Substances 0.000 description 2
230000007958 sleep Effects 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000009736 wetting Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
HKLCDVMUDCZCCA-UHFFFAOYSA-N 2-methyl-3,4-dihydro-2h-naphthalene-1-thione Chemical compound C1=CC=C2C(=S)C(C)CCC2=C1 HKLCDVMUDCZCCA-UHFFFAOYSA-N 0.000 description 1
WQTFKYLFKOBGSG-UHFFFAOYSA-N 3,4,5-triethoxyaniline Chemical compound CCOC1=CC(N)=CC(OCC)=C1OCC WQTFKYLFKOBGSG-UHFFFAOYSA-N 0.000 description 1
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
RDHNWLRUWCOIBI-UHFFFAOYSA-N 5,6-dihydrobenzo[h]quinazoline;hydrochloride Chemical compound Cl.C1=CC=C2CCC3=CN=CN=C3C2=C1 RDHNWLRUWCOIBI-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
108091005482 5-HT4 receptors Proteins 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
VFEGSUSXYTVCKX-UHFFFAOYSA-N 6-chloro-1-oxo-3,4-dihydro-2h-naphthalene-2-carbaldehyde Chemical compound O=C1C(C=O)CCC2=CC(Cl)=CC=C21 VFEGSUSXYTVCKX-UHFFFAOYSA-N 0.000 description 1
WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 1
NTVKOYKLIKUWHM-UHFFFAOYSA-N 6-methoxy-1-oxo-3,4-dihydro-2h-naphthalene-2-carbaldehyde Chemical compound O=C1C(C=O)CCC2=CC(OC)=CC=C21 NTVKOYKLIKUWHM-UHFFFAOYSA-N 0.000 description 1
MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 1
CTTWVNGSZLDQOF-UHFFFAOYSA-N 7-methoxy-1-oxo-3,4-dihydro-2h-naphthalene-2-carbaldehyde Chemical compound C1CC(C=O)C(=O)C2=CC(OC)=CC=C21 CTTWVNGSZLDQOF-UHFFFAOYSA-N 0.000 description 1
DWIQWGSWCURXCT-UHFFFAOYSA-N 7-methoxy-2-(methoxymethylidene)-3,4-dihydronaphthalen-1-one Chemical compound C1=C(OC)C=C2C(=O)C(=COC)CCC2=C1 DWIQWGSWCURXCT-UHFFFAOYSA-N 0.000 description 1
GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 1
GYYBQENWKAJVKY-UHFFFAOYSA-N 8-chloro-2-methyl-3,4-dihydro-2h-naphthalene-1-thione Chemical compound C1=CC(Cl)=C2C(=S)C(C)CCC2=C1 GYYBQENWKAJVKY-UHFFFAOYSA-N 0.000 description 1
LTNCNYNASICNPI-UHFFFAOYSA-N 8-methoxy-2-(4-methoxyphenyl)-5,6-dihydrobenzo[h]quinazoline;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1=NC=C(CCC=2C3=CC=C(OC)C=2)C3=N1 LTNCNYNASICNPI-UHFFFAOYSA-N 0.000 description 1
HSJHCCNHBIUUAI-UHFFFAOYSA-N 8-methoxy-2-pyridin-4-yl-5,6-dihydrobenzo[h]quinazoline;hydrochloride Chemical compound Cl.C=1C(OC)=CC=C(C2=N3)C=1CCC2=CN=C3C1=CC=NC=C1 HSJHCCNHBIUUAI-UHFFFAOYSA-N 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
101710171573 Primary amine oxidase Proteins 0.000 description 1
101000761350 Rattus norvegicus 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000000338 anxiogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000005286 illumination Methods 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
206010021654 increased appetite Diseases 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000009413 insulation Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
238000003819 low-pressure liquid chromatography Methods 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229940096826 phenylmercuric acetate Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
VBUBADWLHFZFDK-UHFFFAOYSA-N quinazoline;hydrochloride Chemical compound Cl.N1=CN=CC2=CC=CC=C21 VBUBADWLHFZFDK-UHFFFAOYSA-N 0.000 description 1
150000003246 quinazolines Chemical class 0.000 description 1
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
230000000862 serotonergic effect Effects 0.000 description 1
230000003860 sleep quality Effects 0.000 description 1
230000004622 sleep time Effects 0.000 description 1
230000037322 slow-wave sleep Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

NO981477A 1995-10-02 1998-04-01 Pyrimidinderivater som 5HT2C-reseptor antagonister NO310072B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US473395P	1995-10-02	1995-10-02
PCT/EP1996/004099 WO1997012880A1 (fr)	1995-10-02	1996-09-19	Derives de pyrimidine en tant qu'antagonistes du recepteur de 5ht¿2c?

Publications (3)

Publication Number	Publication Date
NO981477D0 NO981477D0 (no)	1998-04-01
NO981477L NO981477L (no)	1998-06-02
NO310072B1 true NO310072B1 (no)	2001-05-14

Family

ID=21712250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO981477A NO310072B1 (no)	1995-10-02	1998-04-01	Pyrimidinderivater som 5HT2C-reseptor antagonister

Country Status (23)

Country	Link
US (1)	US5753663A (fr)
EP (1)	EP0856001B1 (fr)
JP (1)	JP3071830B2 (fr)
KR (1)	KR100258052B1 (fr)
CN (1)	CN1118460C (fr)
AR (1)	AR004516A1 (fr)
AT (1)	ATE222892T1 (fr)
AU (1)	AU700637B2 (fr)
BR (1)	BR9610823A (fr)
CA (1)	CA2233003A1 (fr)
CZ (1)	CZ98998A3 (fr)
DE (1)	DE69623306T2 (fr)
DK (1)	DK0856001T3 (fr)
EA (1)	EA001311B1 (fr)
ES (1)	ES2180798T3 (fr)
HU (1)	HUP9802323A3 (fr)
IL (1)	IL123581A (fr)
MX (1)	MX9802383A (fr)
NO (1)	NO310072B1 (fr)
NZ (1)	NZ319158A (fr)
PL (1)	PL326083A1 (fr)
PT (1)	PT856001E (fr)
WO (1)	WO1997012880A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9222253D0 (en) *	1992-10-23	1992-12-09	Celltech Ltd	Chemical compounds
GB9304920D0 (en) *	1993-03-10	1993-04-28	Celltech Ltd	Chemical compounds
GB9304919D0 (en) *	1993-03-10	1993-04-28	Celltech Ltd	Chemical compounds
US6245774B1 (en)	1994-06-21	2001-06-12	Celltech Therapeutics Limited	Tri-substituted phenyl or pyridine derivatives
US5786354A (en) *	1994-06-21	1998-07-28	Celltech Therapeutics, Limited	Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en)	1994-06-22	1994-08-10	Celltech Ltd	Chemical compounds
GB9412571D0 (en)	1994-06-22	1994-08-10	Celltech Ltd	Chemical compounds
ATE198326T1 (de) *	1995-04-20	2001-01-15	Pfizer	Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
GB9622363D0 (en) *	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
US6057329A (en) *	1996-12-23	2000-05-02	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives
GB9705361D0 (en) *	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
GB9713087D0 (en) *	1997-06-20	1997-08-27	Celltech Therapeutics Ltd	Chemical compounds
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
GB9924862D0 (en) *	1999-10-20	1999-12-22	Celltech Therapeutics Ltd	Chemical compounds
US20030176454A1 (en) *	2000-05-15	2003-09-18	Akira Yamada	N-coating heterocyclic compounds
MEP13408A (en) *	2001-05-29	2010-06-10	Bayer Schering Pharma Ag	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
UA80767C2 (en) *	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (fr)	2002-12-20	2009-12-15	Pfizer Products Inc.	Derives de pyrimidine destines au traitement de la croissance cellulaire anormale
CN1897950A (zh)	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
US20060205945A1 (en) *	2004-05-14	2006-09-14	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
EP1751142A1 (fr)	2004-05-14	2007-02-14	Pfizer Products Incorporated	Derives pyrimidiques pour le traitement de la croissance de cellules anormales
WO2005111024A1 (fr)	2004-05-14	2005-11-24	Pfizer Products Inc.	Derives de pyrimidine destines au traitement de croissance cellulaire anormale
MXPA06013165A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
JP4774436B2 (ja) *	2005-03-15	2011-09-14	エフ．ホフマン−ラロシュアーゲー	５ｈｔ５ａレセプターアンタゴニストとしての２−アニリノ−３，４−ジヒドロ−キナゾリンの使用
WO2009081222A1 (fr)	2007-12-21	2009-07-02	Glenmark Pharmaceuticals, S.A.	Pyrimidines ou pyridines tricycliques substituées ligands des récepteurs des vanilloïdes
PT2358686E (pt) *	2008-11-20	2012-12-06	Merck Sharp & Dohme	Moduladores alostéricos positivos do recetor m1 de aril metil benzoquinazolinona
JP5739820B2 (ja) *	2008-12-30	2015-06-24	アークルインコーポレイテッド	置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
EP2512245B1 (fr) *	2009-12-14	2014-07-23	Merck Sharp & Dohme Corp.	Modulateurs allostériques positifs des récepteurs m1 de pyridoquinazolinone
WO2011084371A1 (fr) *	2009-12-21	2011-07-14	Merck Sharp & Dohme Corp.	Modulateurs allostériques positifs du récepteur m1 à base d'aminobenzoquinazolinone
TWI402264B (zh) *	2010-05-12	2013-07-21	Merck Sharp & Dohme	芳基甲基苯并喹唑啉酮ｍ１受體之正向異位性調節劑
US8735386B2 (en) *	2010-07-23	2014-05-27	Boehringer Ingelheim International Gmbh	Aminopyrazoloquinazolines
US20130190395A1 (en)	2011-12-13	2013-07-25	Dartmouth College	Autoimmune disorder treatment using rxr agonists
CN103214489B (zh) *	2013-02-25	2016-10-26	中国人民解放军第二军医大学	一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3177216A (en) *	1961-12-28	1965-04-06	Searle & Co	4-trifluoromethyl-2-thio-5h-alka[d]-pyrimidines and congeners
US3257400A (en) *	1964-06-10	1966-06-21	Searle & Co	2-amino-5, 6-dihydrobenzo[h]quinazolin-4(3h)-one and congeners
US3925384A (en) *	1974-10-21	1975-12-09	Squibb & Sons Inc	2-Amino-4,5-dihydro-4-arylindeno pyrimidines
JPH07500589A (ja) *	1991-10-24	1995-01-19	メルク　シヤープ　エンド　ドーム　リミテツド	ベンゾジアゼピン誘導体、並びにコレシストキニン及び／又はガストリンレセプターのアンタゴニストとしての該誘導体の使用

1996
- 1996-09-19 AT AT96932569T patent/ATE222892T1/de not_active IP Right Cessation
- 1996-09-19 CN CN96197385A patent/CN1118460C/zh not_active Expired - Fee Related
- 1996-09-19 NZ NZ319158A patent/NZ319158A/en unknown
- 1996-09-19 JP JP9513926A patent/JP3071830B2/ja not_active Expired - Fee Related
- 1996-09-19 IL IL12358196A patent/IL123581A/en not_active IP Right Cessation
- 1996-09-19 CZ CZ98989A patent/CZ98998A3/cs unknown
- 1996-09-19 DK DK96932569T patent/DK0856001T3/da active
- 1996-09-19 EA EA199800340A patent/EA001311B1/ru not_active IP Right Cessation
- 1996-09-19 EP EP96932569A patent/EP0856001B1/fr not_active Expired - Lifetime
- 1996-09-19 AU AU71311/96A patent/AU700637B2/en not_active Ceased
- 1996-09-19 CA CA002233003A patent/CA2233003A1/fr not_active Abandoned
- 1996-09-19 PL PL96326083A patent/PL326083A1/xx unknown
- 1996-09-19 HU HU9802323A patent/HUP9802323A3/hu unknown
- 1996-09-19 PT PT96932569T patent/PT856001E/pt unknown
- 1996-09-19 KR KR1019980702391A patent/KR100258052B1/ko not_active IP Right Cessation
- 1996-09-19 ES ES96932569T patent/ES2180798T3/es not_active Expired - Lifetime
- 1996-09-19 WO PCT/EP1996/004099 patent/WO1997012880A1/fr not_active Application Discontinuation
- 1996-09-19 DE DE69623306T patent/DE69623306T2/de not_active Expired - Fee Related
- 1996-09-19 MX MX9802383A patent/MX9802383A/es not_active IP Right Cessation
- 1996-09-19 BR BR9610823A patent/BR9610823A/pt not_active IP Right Cessation
- 1996-09-24 US US08/719,062 patent/US5753663A/en not_active Expired - Fee Related
- 1996-10-01 AR ARP960104557A patent/AR004516A1/es unknown
1998
- 1998-04-01 NO NO981477A patent/NO310072B1/no unknown

Also Published As

Publication number	Publication date
PT856001E (pt)	2003-01-31
KR19990063918A (ko)	1999-07-26
IL123581A (en)	2001-09-13
ES2180798T3 (es)	2003-02-16
EP0856001B1 (fr)	2002-08-28
US5753663A (en)	1998-05-19
AU7131196A (en)	1997-04-28
AR004516A1 (es)	1998-12-16
EA199800340A1 (ru)	1998-10-29
NZ319158A (en)	1999-10-28
JPH10512288A (ja)	1998-11-24
CN1118460C (zh)	2003-08-20
DE69623306D1 (de)	2002-10-02
MX9802383A (es)	1998-08-30
HUP9802323A2 (hu)	1999-03-29
JP3071830B2 (ja)	2000-07-31
HUP9802323A3 (en)	1999-08-30
WO1997012880A1 (fr)	1997-04-10
IL123581A0 (en)	1998-10-30
NO981477L (no)	1998-06-02
EA001311B1 (ru)	2001-02-26
BR9610823A (pt)	1999-07-13
DK0856001T3 (da)	2002-12-30
CN1198743A (zh)	1998-11-11
KR100258052B1 (ko)	2000-08-01
NO981477D0 (no)	1998-04-01
CZ98998A3 (cs)	1998-10-14
PL326083A1 (en)	1998-08-17
DE69623306T2 (de)	2003-04-17
ATE222892T1 (de)	2002-09-15
AU700637B2 (en)	1999-01-07
EP0856001A1 (fr)	1998-08-05
CA2233003A1 (fr)	1997-04-10

Publication	Publication Date	Title
NO310072B1 (no)	2001-05-14	Pyrimidinderivater som 5HT2C-reseptor antagonister
US5002948A (en)	1991-03-26	3-[4-[4-substituted-1-piperazinyl]-1-butyl]-1H-2,3-dihydroindoles
AU725891B2 (en)	2000-10-26	Aryl pyrimidine derivatives
IE832866L (en)	1984-06-07	4-aminoalkyl-2(3h)-indolones.
US10543211B2 (en)	2020-01-28	Methods and compositions for treating diseases and conditions
NO167661B (no)	1991-08-19	Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,3-disubstituerte indoliner.
EP0520200B1 (fr)	1998-02-18	Composés d'imidazole, leur fabrication et utilisation
CZ290464B6 (cs)	2002-07-17	3-Substituované 3,4-dihydrothieno[2,3-d]pyrimidinové deriváty, jejich příprava a pouľití
FI91748B (fi)	1994-04-29	Menetelmä terapeuttisesti käyttökelpoisten kinolinonijohdannaisten valmistamiseksi
EP0005365B1 (fr)	1982-01-06	Dérivés du pyrano- et thiopyrano(3,4-b)indole, procédés pour leur préparation, et compositions pharmaceutiques les contenant
EP1171439A1 (fr)	2002-01-16	Derives d'azaindole destines au traitement de la depression
JP3057095B2 (ja)	2000-06-26	イサチン誘導体、その製造方法及びその使用方法
EP2521714B1 (fr)	2015-08-12	Composés sulfones aromatiques utiles dans le traitement de maladies du système nerveux central
NO164351B (no)	1990-06-18	Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-alkyl-l-fenyl-2-piperazinoalkylpyrazolin-3-on-forbindelser.
RU2314305C2 (ru)	2008-01-10	Производные 4-(тио- или селеноксантен-9-илиден)-пиперидина или акридина, фармацевтическая композиция на их основе и применение
US5210091A (en)	1993-05-11	Imidazole compounds and their use
CA2327360A1 (fr)	1999-10-14	Derives d'amine indol-3-yl-cyclhexyle utilises dans le traitement de la depression (antagonistes du recepteur 5-ht1)
US6162803A (en)	2000-12-19	Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression
US6337336B1 (en)	2002-01-08	Azaindole derivatives for the treatment of depression
EP0743946A1 (fr)	1996-11-27	Indoles condenses a titre d'antagonistes des recepteurs de 5ht 2b?
EP1140919B1 (fr)	2002-09-04	Antidepresseurs a base de derives de cyclohexane 1,4-disubstitues pour le traitement des depressions
US7053108B2 (en)	2006-05-30	Indoline compounds
US6313114B1 (en)	2001-11-06	3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]- amines
US6200994B1 (en)	2001-03-13	1,4-Disubstituted cyclohexane derivatives for the treatment of depression
US6221863B1 (en)	2001-04-24	3,4-dihydro-2H-benzo[1,4]oxazine derivatives